Date: 2013-04-15
Type of information: Fundraising
Company: Avilex Pharma (Denmark)
Investors: Novo Seeds (Denmark)
Amount: undisclosed
Funding type: seed funding
Planned used: This seed funding will be used to support the development of novel dimeric ligands targeting PDZ domains
Others: Avilex Pharma, a spin-out company from the university of Copenhagen, has announced the raising of undisclosed seed funding from Novoseed. This Danish biotech company is based on the technology developed by Professor Kristian Strømgaard, Dr. Anders Bach and their team at the Department of Drug Design and Pharmacology of the University of Copenhagen. Through the use of innovative dimeric ligands, Avilex Pharma can target well established intracellular targets with unprecedented potency with the aim of developing novel medicines for a range of areas of unmet medical need. Avilex lead compounds provide high potency against the protein PSD-95 involved in NMDA receptor signaling and the company will initially focus on the treatment of neuropathic pain.
Avilex Pharma’s Board will be chaired by Mrs. Ingelise Saunders, former CEO of Action Pharma. She will be joined on the Board by Dr. Raymond Hill, ex-head of neuroscience R&D at MSD and Dr. Henrijette Richter of Novo Seeds.
Therapeutic area: CNS diseases - Neurological diseases
